Intellia Therapeutics (NTLA) stock is soaring 7.70% in pre-market trading on Monday, following Evercore ISI analyst Liisa Bayko's reiteration of a Buy rating on the company. The analyst maintained a price target of $48.00 for the stock, signaling confidence in the biotech firm's potential.
The positive analyst sentiment appears to be driving investor optimism, contributing to the significant pre-market surge. Evercore ISI's maintained Buy rating suggests that the firm believes Intellia Therapeutics has strong growth prospects and may be undervalued at its current price levels.
As the market opens, investors will be watching closely to see if this pre-market momentum carries through the regular trading session. The sustained bullish outlook from a respected analyst could potentially attract more buyers and further boost the stock's performance. However, as always, investors should conduct their own research and consider multiple factors before making investment decisions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。